Articles

A wealth of abstracts were presented at the 54th Annual Meeting of the American Society of Hematology (ASH), held in Atlanta, Georgia, on December 8-11, 2012. More than 18,000 hematologists and other healthcare professionals from around the world gathered to discuss the latest clinical developments in research, therapies, and practice strategies. Below are some of the highlights from that meeting.

For preventing bone metastases in women with early breast cancer, the current body of evidence does not support the use of osteoclast-targeting agents, ie, bisphosphonates, according to Julie Gralow, MD, director of Breast Medical Oncology at the Fred Hutchinson Cancer Research Center in Seattle, Washington.

Bayesian networks based on single nucleotide polymorphisms (SNPs), developed from saliva-sourced DNA, can be used to predict the occurrence of adverse effects associated with chemotherapy.

Researchers have discovered that consuming a daily dose of omega-3 fish oils enhances skin immunity to sunlight.

The National Lung Screening Trial found that LDCT screening reduces lung cancer deaths by about 20% compared with chest x-ray.

Novel cancer care technology now allows doctors to treat prostate cancer from within the body.

The FDA recently approved a new therapy for patients with HER2-positive, metastatic breast cancer who had previously received treatment with trastuzumab and taxanes.

The FDA expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors.

A recent study found that national guidelines pertaining to the average number of polyps routinely detected during colonoscopy may be too low.

Recent studies have shown that, when compared with the conventional x-ray test of barium enema, a CT colonography is more effective when an examination of bowel cancer symptoms is required.